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CD8+ cytotoxic T lymphocytes (CTLs) and natural killer (NK)
cells play a major and complementary role in eliminating virally
infected or otherwise antigenically modified cells (e.g. neoplastic
cells) (Kos and Engleman, 1996). CTL responses are ‘MHC class
I restricted’, as their activation is dependent on class I major histo-
compatibility molecules (MHC). MHC class I molecules transport
peptides derived from proteins produced intracellularly to the
surface of the cell, allowing recognition by specific T-cell recep-
tors (TCRs) and CD8 molecules present on the surface of CTLs
(Parham, 1995). MHC class I molecules consist of a polymorphic
heavy chain, encoded within the classical MHC loci (HLA-
A,B,C), which is stablized by a constant non-covalent associated
light chain, b2-microglobulin (b2-m).
In contrast to CTLs, natural killer (NK) cells do not harbour
TCRs on the cellular membrane, and their activation does not
require MHC class I expression by the target cell, neither do they
develop immunological memory (Yokoyama, 1995). Instead, and
in addition to receptors that receive stimulatory signals (e.g. NKR-
P1, CD2, CD16, CD69), NK cells have killer-cell inhibitory recep-
tors (KIRs) that recognize polymorphic determinants on MHC
class I molecules of their target cells. Some of the KIRs identified
belong to the immunoglobulin superfamily and specifically recog-
nize groups of HLA-C (e.g. p58), HLA-B (e.g. p70) and HLA-A
alleles (p140) (Mingari et al, 1998). Other KIRs belong to the
C-type lectin superfamily (e.g. CD94/NKG2A) and display a less
well-defined allele specificity (Mingari et al, 1998). In contrast to
CTLs which bear only one TCR per CTL, in NK cells several
KIRs may be present per NK cell. Only when their target cells fail
to express the relevant MHC class I allele(s), NK cells will be
released from the inhibitory signals conveyed by the respective
KIRs, and full activation of NK cells may ensue (Yokoyama,
1995; Lanier and Phillips, 1996).
When proper activation of cytotoxic cells occurs, killing of the
target cell may occur. Two main pathways of fast-acting cytotoxi-
city have been described for CTLs, both activating the caspase
cascade and resulting in apoptosis of the target cell (Berke, 1997).
In the ‘secretory pathway’ perforin and granzymes present in
granules of the cytotoxic cell, are released in the direct vicinity of
the target cell. Perforin forms pores in the membrane of the target
cell, allowing the entrance of granzyme B in its cytoplasm, which
in turn will activate the caspase cascade (Froelich et al, 1998). In
the ‘non-secretory pathway’, Fas ligand (Fas-L) expressed on the
surface of the cytotoxic cell upon activation, will bind Fas when
this is expressed on the surface of the target cell (Berke, 1997).
This interaction will also result in the activation of the caspase
cascade with subsequent apoptosis of the target cell. According to
some reports NK cells only use the ‘secretory pathway’ as a mech-
anism of cytotoxicity (van den Broek et al, 1995; Kagi et al, 1996).
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Summary Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells use the secretory pathway of perforin/granzymes to kill their target
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by immunohistochemistry using HCA2, HC10 and b2-m antibodies. The presence of CTLs, NK cells, and its activation, was investigated in 21
of these OSCCs using respectively, CD8, CD57 and GrB7 antibodies. The Q-Prodit measuring system was used for quantification of cytotoxic
cells. All OSCCs showed weak or absent staining of b2-m on the cell surface. The absence of b2-m was significantly associated with absent
expression of MHC class I heavy chain as detected by HC10 antibody (P = 0.004). In tumour infiltrates CTLs always outnumbered NK cells,
as reflected by the ratio CD57/CD8 being always inferior to one (mean: 0.19; SD: 0.15). The proportion of activated cytotoxic cells as detected
by granzyme B expression was generally low (mean: 8.6%; SD 8.9). A clear correlation between MHC class I expression and the relative
proportion of NK cells/CTLs was not found. This study shows that the majority of OSCCs show weak or absent expression of MHC class I
molecules on the cell surface, possibly due to alterations in the normal b2-m pathway. The low proportion of granzyme B-positive CTLs/NK
cells indicates that the secretory pathway of cytotoxicity is poor in these patients. The lack of correlation between MHC class I expression and
CTL/NK cell activation as detected by granzyme B expression suggests that, next to poor antigen presentation, also local factors seem to
determine the final outcome of the cytotoxic immune response. © 1999 Cancer Research Campaign
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neoplastic cells use to evade the immune response, we analysed
MHC class I expression in neoplastic cells of oral squamous cell
carcinomas (OSCCs) using antibodies to the polymorphic heavy
chains (HCA2 and HC10) and b2-m. Moreover, in relation with
MHC class I expression we analysed the presence of CD8- and
CD57-positive cells, and investigated whether the granzyme
pathway was activated.
MATERIALS AND METHODS
Patients and tissues
Forty-seven formalin-fixed, paraffin-embedded surgical OSCC
specimens from patients that were seen at the Department of Oral
& Maxillofacial Surgery and Otorhinolaryngology from the Free
University Hospital, Amsterdam, The Netherlands, were evaluated
in this study. In 23 of these OSCCs, tumour adjacent normal or
dysplastic mucosa was present in the same paraffin block of the
carcinoma and was evaluated for MHC class I expression.
Histologically normal epithelium at the surgical resection margin
of six of these OSCCs and present in a different paraffin block
from that containing the carcinoma, and eight clinically and histo-
logically normal epithelium from healthy individuals subjected to
third molar extractions, were also analysed for MHC class I
expression.
Immunohistochemical analysis
Four-micrometre sections from formalin-fixed, paraffin-
embedded tissues were mounted on poly-L-lysine, or 3-amino-
propyl-triethoxy-silane (APES)-coated slides. Consecutive
sections were used as negative control of the immunohisto-
chemical (IHC) reaction and for haematoxyline and eosin (H&E)
staining to confirm the diagnosis.
The streptavidin–biotin complex immunoperoxidase technique
used was previously described in detail (Cruz et al, 1998).
Microwave antigen retrieval was performed for HCA2 in ‘target
unmasking fluid’ (TUF) at 95°C, and for CD8, CD57 and GrB7 in
citrate at 100°C (3 ´ 5 min). Primary antibodies were incubated, at
room temperature, for 1 h: (a) monoclonal antibody (mAb) HCA2
(1:500) recognizing preferentially HLA-A locus products (Stam
et al, 1990); (b) mAb HC10 (1:1000), recognizing preferentially
HLA-B/C locus products (Stam et al, 1986); (c) polyclonal
rabbit-anti-b2-microglobulin (Dako) (1/50), recognizing the
constant/light chain of MHC class I molecule; (d) anti-CD8 (Clone
C8144B, Dako) (1/50), a mouse monoclonal antibody which
recognizes the CD8 molecule on the surface of
cytotoxic/suppressor T-cells; (e) anti-CD57 (Zymed) (1/25), a
mouse monoclonal which recognizes the CD57, an antigen associ-
ated with NK cells and a subset of human T-cells; (f) GrB7
(1/500), monoclonal antibody raised against recombinant
granzyme B protein and specific for human granzyme B (Kummer
et al, 1993, 1995). For b2-m, the only polyclonal antibody used,
normal swine serum (1:10) and swine anti-rabbit (1:200) were
used as normal serum and secondary antibody respectively. After
the secondary antibody all cases were incubated with strepta-
vidin–biotin complex horseradish peroxidase (1:200) for 1 h. The
catalysed reporter deposition (CARD) method (Bobrow et al,
1989) was used for signal amplification of CD8 IHC. Negative
controls consisting of phosphate-buffered saline (PBS) instead of
primary antibody, and sections of a hyperplastic tonsil used as
positive control, were included in each experience.
Quantification of IHC results
MHC class I status of the lesions was scored under conventional
light microscopy as follows. Cells were considered positive only
when the staining was found on the cellular membrane. The MHC
class I expression pattern of normal or dysplastic oral mucosa was
classified in three categories: (–): no staining apparent; (+):
staining confined to the basal/parabasal layers of the epithelium;
(++): staining reaching spinous layer; (+++): staining reaching
superficial layers of the epithelium.
The staining intensity of non-malignant oral epithelium adjacent
to carcinoma, and the staining of inflammatory infiltrate, were
used as a reference to define strong and weak staining in OSCCs.
MHC class I expression patterns of individual carcinoma cases
were divided into three categories, according to the intensity and
number of positive cells: (–): less than 25% positive cells; (+/–):
more than 25% and less than 75% positive cells, or more than 75%
weakly positive cells; (+): more than 75% strong positive cells.
For statistical analysis the categories (+/–) and (+), as defined
above, were considered together defining a single
category of ‘positive cases’.
To estimate the proportion of CTLs, NK cells and activated
cytotoxic cells, CD8, CD57 and GrB7 positive cells were quanti-
fied using a commercially available interactive video overlay
based measuring system (Q-Prodit, Leica, Cambridge, UK)
(Brinkhuis et al, 1995). Neoplastic areas and respective inflamma-
tory infiltrate were selected by us, under low power view. One
hundred fields of vision (FOV) were evaluated using systematic
random sampling, whereby the first FOV was chosen at random
within the measurement area, and the subsequent fields were
chosen systematically by adjusting the distance between the FOV
in proportion to the area of tissue considering for sampling. These
selections were made using an automated scanning stage
controlled by Prodit. Eight points were counted per FOV using a
Weibel test grid under a 40´ objective (final magnification in the
computer screen: 1200´). In each case, the numbers of CD8+,
CD57+ and granzyme B+ cells were counted in similar areas of
the carcinoma. The ratio between NK cells and CTLs was esti-
mated by calculating the ratio between CD57+ cells and CD8+
cells in similar areas. The proportion of activated cytotoxic cells
was estimated by calculating the ratio between granzyme B+ cells
and the total number of CD57+ and CD8+ cells in similar areas.
The proportion of activated CTLs was ‘(over)estimated’ by calcu-
lating the ratio between granzyme B+ cells and CD8+ cells in
similar areas.
Statistical analysis
Statistical analysis was performed using SPSS 7.0 software.
Fisher’s exact test was used to compare cell surface expression of
MHC class I heavy chains and b2-microglobulin. The ratio
between NK cells and CTLs, and the proportion of activated
cytotoxic cells as detected by granzyme B expression, were
compared with cell surface expression of MHC class I using the
Mann–Whitney two-sample test and the Wilcoxon signed rank
test. Values were considered significantly different when P was
less than 0.05.
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Table 1 shows the most relevant clinical and pathological data of
the tumour cases. The MHC class I expression on the surface of
neoplastic cells, and the ratio between NK cells and CTLs,
percentage of activated cytotoxic cells and the percentage of acti-
vated CTLs are presented in Table 1.
MHC class I expression
All tumours exhibited strongly MHC class I immunopositive
inflammatory cells validating the success of the immune tech-
nique. Negative controls, consisting of PBS or IgG of the same
subclass instead of the primary antibody, confirmed the specificity
of the membranous staining.
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British Journal of Cancer (1999) 81(5), 881–889 © 1999 Cancer Research Campaign
Table 1 Clinicopathological data, MHC class I expression on tumour cells and proportion of (activated) cytotoxic cells
Tn Gend/Age Locat Grade b2-m HC10 HCA2 CD57:CD8 GrB7/CD8+CD57 GrB7/CD8
(%) (%)
1 F/63 T W-M – – – 0.09 0 0
2 M/45 OL P – – – 0.07 0 0
3 M/60 OL W-M – – – 0.08 37 46
4 F/87 FM M-P – – – 0.11 3 3
5 M/71 T/FM W-M – – –
6 F/55 FM W-M – – –
7 M/77 OL W – – –
8 M/70 FM M – – +/– 0.27 22 27
9 M/72 T M – – +/– 0.13 15 16
10 F/49 FM W-M – – +/–
11 F/75 T M – – +
12 M/67 T M – +/– +/– 0.15 7 9
13 M/48 OL M – +/– +/– 0.22 10 13
14 M/58 OL M-P – +/– +/–
15 M/69 T W-M – +/– +/–
16 F/51 FM W-M – +/– +/–
17 M/75 T W-M – +/– nd
18 M/59 T W-M nd +/– – 0.45 4 6
19 M/81 T M nd – – 0.08 7 10
20 M/76 OL W-M nd nd –
21 F/86 T W-M +/– nd –
22 F/69 T W-M +/– – nd
23 F/56 OL M +/– – – 0.29 11 13
24 M/62 T M +/– – +/– 0.05 1 1
25 M/59 FM M +/– – +/–
26 M/55 T W-M +/– – +/–
27 F/45 OL M-P +/– +/– – 0.10 6 8
28 F/63 T W +/– +/– – 0.63 2 3
29 F/80 T M +/– +/– – 0.33 17 24
30 F/73 OL W-M +/– +/– –
31 M/52 OL W +/– +/– –
32 F/47 OC M +/– +/– nd
33 F/55 T W-M +/– +/– +/– 0.16 8 10
34 F/81 OL W +/– +/– +/– 0.04 1 1
35 F/82 T M +/– +/– +/– 27
36 M/39 T W +/– +/– +/–
37 M/63 FM W +/– +/– +/–
38 M/70 T W-M +/– +/– +/–
39 M/81 T W-M +/– +/– +/–
40 M/68 T W-M +/– +/– +/–
41 F/57 T W +/– +/– +
42 M/59 OL W +/– + +/– 0.12 5 6
43 F/79 T W +/– + +/– 0.34 8 11
44 M/48 T W-M +/– + +/–
45 F/28 T W-M +/– + +
46 F/84 FM M +/– + + 0.12 7 8
47 M/56 T W-M +/– + +
Tn = Tumour number. Gend/Age = Gender/Age: M = Male; F = Female. Locat = Location of tumour: T = Tongue; FM = Floor of mouth; OL = Other location
(within the oral cavity); OC=Oral cavity (location not specified). Grade = grade of differentiation: W=Well dif. SCC; W-M=Well to moderately dif. SCC;
M=Moderately dif. SCC; M-P=Moderately to poor dif. SCC; P=Poor dif. SCC. b2-m, Hc10/HcA2 = MHC class I light and heavy chain expression at the surface
of neoplastic cells: (–), (+/–), (+) = score system defined in Materials and Methods. CD57/CD8: ratio between number of NK cells and number of CTLs;
GrB7/CD8+CD57: percentage of activated cytotoxic cells; GrB7/CD8: percentage of activated CTLs (overestimated).MHC class I expression in non-malignant mucosa
The MHC class I staining patterns of non-malignant mucosa
obtained from healthy individuals and mucosa adjacent to and
distant from the tumour in OSCC patients are depicted in Table 2.
The  b2-m staining was generally stronger than the staining
obtained with HC10 in all three groups of non-malignant mucosa
analysed (Table 2). In addition, increasing staining was observed
with both b2-m and HC10 antibodies, when comparing normal
mucosa of healthy individuals with normal mucosa in OSCCs’
resection margins, and when comparing the latter with mucosa
immediately adjacent to OSCCs (Table 2). However, a consider-
able variation in MHC class I expression occurred among 
individuals. Therefore, we also compared the staining patterns
obtained in the OSCC’s resection margin and in the mucosa
adjacent to OSCC of the same patient, in six cases where this data
was available. In four cases (67%) there was an increase in b2-m
and HC10 staining in the tumour adjacent mucosa when compared
to the more distant and histologically normal epithelium of the
tumour resection border. In the remaining two cases (33%) a
similar staining pattern was found in adjacent mucosa and the
histologically normal resection margin of OSCC (++/++ and
+++/+++ respectively).
Non-malignant mucosa immediately adjacent to carcinoma often
showed strong expression of MHC class I molecules (Figure 1, A1,
A2, C1, C2), either in dysplastic or histologically normal epithe-
lium, and independently of the pattern of MHC class I expression in
the adjacent carcinoma. Besides the basal epithelial layer, the upper
spinous layers of the non-malignant epithelium were often stained,
even with antibodies against MHC class I heavy chains (Figure 1,
A,C). This was in contrast to the weak staining found in normal
mucosa of healthy individuals that, when present, was confined to
the basal/parabasal epithelial layers (Table 2).
We also compared MHC class I expression on the non-malig-
nant mucosa adjacent to carcinoma with the staining observed in
the respective OSCC of the same patient, in 23 cases where this
data was available. Only in three out of these cases (13%), the
strong expression detected in the adjacent non-malignant mucosa
was maintained in the respective OSCC. These results were only
obtained with the HC10 antibody (Figure 1 C2/D2). For b2-m the
respective carcinoma showed weak staining on the tumour cells, in
spite of the fact that the tumour adjacent mucosa showed strong
staining (Figure 1 C1/D1). In the remaining twenty cases the
tumour showed weak or absent expression of MHC class I, either
by using HC10 or b2-m.
MHC class I expression in OSCCs
All carcinomas analysed with b2-m antibody (n = 44) showed
weak or absent b2-m staining at the surface of the neoplastic cells.
Seventeen (39%) showed less than 25% positive tumour cells
(score-, as previously defined) (Figure 1, B1), and 27 carcinomas
(61%) showed more than 25% positive tumour cells, usually
weakly stained (score +/–) (Figure 1, D1 and Table 1).
Out of 45 carcinomas analysed with HC10, 39 (87%) showed
weak or absent MHC class I heavy chain expression in the cellular
membrane. Seventeen (38%) were scored (–), and 22 (49%)
were scored (+/–). Six carcinomas (13%) were strongly positive
(score +) (Figure 1, D2 and Table 1). A significant association
was found between immuno-negative/positive staining for b2-m
and immuno-negative/positive staining for HC10 respectively
(P = 0.004) (Table 3).
Out of 44 carcinomas analysed with HCA2, 39 (89%) showed
weak or absent expression of MHC class I heavy chain in the
cellular membrane. Seventeen (39%) were scored (–) (Figure 1,
B2), and 22 (50%) were scored (+/–). Five carcinomas (11%) were
scored (+) (Table 1). No significant association was found between
HCA2 and b2-m immunostaining (P = 0.332).
(Co-)expression of MHC class I light and heavy chains, at
the surface of neoplastic cells
Forty carcinomas were analysed both with the antibody directed
against MHC class I light chain (b2-m) and with the antibodies
against MHC class I heavy chains (HC10 and HCA2). In the
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Table 2 MHC class I expression, as detected by b2-m and HC10 antibodies, in non-malignant oral mucosa
b2-m HC10
– + ++ +++ – + ++ +++
NOM 0 1 7 0 2 6 0 0
(Healthy indiv.) 12.5% 87.5% 25% 75%
NOM 0 2 3 1 0 3 2 1
(Res.Mar.OSCC) 33% 50% 17% 50% 33% 17%
NOM/DYS 0 0 10 13 0 2 13 8
(Adj.Muc.OSCC) 43% 57% 9% 56% 35%
NOM (Healthy indiv.): clinically and histologically normal oral mucosa from healthy individuals; NOM (Res.Mar.OSCC): histologically normal mucosa from the
surgical resection margin of OSCC; NOM/DYS (Adj.Muc.OSCC): histologically normal or dysplastic epithelium immediately adjacent to OSCC. (–): no staining
apparent; (+) staining confined to basal/parabasal cell layers; (++): staining reaching spinous layer of the epithelium; (+++): staining reaching superficial layers
of the epithelium.
Table 3 Association between light (b2-m) and heavy (HLA-B/C) chains of
MHC class I, at the cell surface of OSCCs, as detected by
immunohistochemistry
b2-M (Light chain)
Heavy chain (–) (+) ND P-value*
HC10 (n = 43) (–) 11 (69%) 5 (31%) 1 P=0.004
(+) 6 (22%) 21 (78%) 1
N D –11
HC10: monoclonal antibody that detects preferentially HLA-B/C heavy chains
of MHC class I b2-m: polyclonal antibody that detects the light chain (b2-m)
of MHC class I molecules. (–): <25% + cells; (+): >25% positive cells; ND: not
done. *statistics performed using Fisher’s exact test.MHC class I and cytotoxic cells in OSCCs 885
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Figure 1 (A) Non-malignant mucosa adjacent to OSCC (Table 1, T4) showing strong expression of MHC class I light and heavy chains in the cell membrane;
(A1) IHC performed with b2-m antibody; (A2) IHC performed with HCA2 antibody. (B) OSCC adjacent to the non-malignant mucosa shown in A (Table 1, T4)
showing neoplastic cells without any membranous staining (–) for MHC class I light and heavy chains: (B1) IHC performed with b2-m antibody shows no
membranous staining, although cytoplasmatic staining is present; (B2) IHC performed with HCA2 antibody shows neither membranous or cytoplasmatic
staining in the tumour cells. Dendritic cells are positive. (C) Non-malignant mucosa adjacent to OSCC (Table 1, T46) showing strong expression of MHC class I
light and heavy chains in the cell membrane; (C1) IHC performed with b2-m antibody; (C2) IHC performed with HC10 antibody. (D) OSCC adjacent to the non-
malignant mucosa shown in C (Table 1, T46) showing: (D1) weak expression (+/–) of the MHC class I light chain (b2-m) in the cell membrane; (D2) strong
membranous staining (+) for the MHC class I heavy chain, as detected by HC10 antibody. Size bars represent 30 mmremaining seven cases, results for b2-m (n = 3), HC10 (n = 2) and
HCA2 (n = 3) were not available, and these cases were excluded
from this analysis. In seven carcinomas (17.5%) a simultaneous
loss of light and heavy chains was apparent, as reflected by
absence of staining with b2-m and HC10/HCA2 antibodies
respectively (Table 1, cases T1–T7). In nine cases (22.5%) the
heavy chain could be detected on the cell surface, in the absence of
the light chain: these included four cases in which only HCA2
gave positive results (Table 1, cases T8–T11) and five cases that
were positive with both HC10 and HCA2 antibodies (Table 1,
cases T12–T16). In one case (2.5%) the light chain could be
detected in the absence of detectable heavy chains (Table 1, case
T23). In eight cases (20%) expressing the light chain at the cell
surface only heavy chains corresponding to a certain HLA loci
(HLA-B/C versus HLA-A, as reflected by HC10 or HCA2 staining
respectively) could be detected: three cases were detected with
HCA2 (Table 1, cases T24–T26) and five cases were detected with
HC10 (Table 1, cases T27–T31). Finally, in 15 cases (37.5%) both
light and heavy chains of both HLA loci (HLA-B/C and HLA-A)
were detected in the surface of neoplastic cells (Table 1, cases
T33–T47).
Proportion of activated cytotoxic cells (CTL and NK
cells) infiltrating OSCCs as detected by granzyme B
expression
In order to estimate the proportion of activated cytotoxic cells
(CTLs and NK cells) the expression of CD8, CD57 and granzyme
B7 was analysed, by IHC, in consecutive sections of 21 OSCCs
tested for MHC class I expression. The results are depicted in
Table 1 and a representation of them is shown in Figure 2.
The ratio between NK cells and CTLs infiltrating the tumour,
was estimated by calculating the ratio between CD57+ and CD8+
cells in consecutive sections of the OSCCs. CTLs always out-
numbered NK cells, although the relative proportion of these two
varied among different OSCCs. The ratio between NK cells and
CTLs ranged from 0.04 to 0.63 (mean: 0.19; SD 0.15) (Table 1 and
Figure 2 A2,A3,B2,B3).
The proportion of activated cytotoxic cells (CTLs and NK cells)
was estimated by calculating the proportion of CD8+ and CD57+
cells that were granzyme B-positive. This proportion indicated
that 0% to 37% of the cytotoxic cells were activated in the OSCCs
analysed (mean: 8.6%; SD 8.9) (Table 1 and Figure 2 A4, B4). In
addition, and since the CD8+ population was the population of
cytotoxic cells more represented in the OSCC, we also calculated
the proportion of CD8+ cells that were granzyme B+, bearing in
mind that this ratio may overestimate the proportion of activated
CTLs due to inclusion of some activated cells that belong to the
NK cell population, particularly in MHC class I-negative cases.
These proportion ranged from 0% to 46% (mean: 11.52%; SD
11.35) (Table 1).
No correlation between MHC class I expression and the rela-
tive proportion of NK cells/CTLs was found (Table 1 and Figure
2). Similarly, no correlation was found between the proportion of
activated cytotoxic cells, as detected by granzyme B/CD57+CD8,
and the relative expression of MHC class I (Table 1). Never-
theless, in general, the proportion of activated cytotoxic cells was
poor, as reflected by the mean value for granzyme B+ cytotoxic
cells (8.6%). This is in agreement with the finding that in 
general all OSCCs analysed had alterations in the MHC class I
expression.
DISCUSSION
In the present study we found weak or absent expression of MHC
class I molecules on the surface of neoplastic cells, in the majority
of OSCCs studied, probably due to alterations in the b2-m
pathway. In addition, activation of cytotoxic cells (i.e. CTLs and
NK cells) as detected by granzyme B expression in CD8+ and
CD57+ cells, was remarkably low.
MHC class I expression in non-malignant mucosa
Inflammatory infiltrating cells were always strongly positive and
were used as an internal positive control for each sample analysed.
The MHC class I expression pattern of normal oral mucosa from
healthy individuals was compared with normal oral mucosa present
in the resection margin of OSCCs and with oral mucosa immedi-
ately adjacent to OSCCs. Although inter-individual variation
occurred, generally, the highest MHC class I expression was found
immediately adjacent to OSCCs, either in normal or dysplastic
epithelium, and the lowest expression was found in normal oral
mucosa from healthy individuals. Intermediate levels of MHC class
I expression occurred in the histologically normal oral mucosa
present in the resection margins of OSCCs. This suggests up-
regulation of MHC class I expression during the initial steps of oral
carcinogenesis, although the extent to which this occurs vary
among different individuals. The generalized weak expression of
MHC class I found among OSCCs, suggests that this mechanism of
up-regulation fails upon progression towards malignancy. We tried
to illustrate this hypothetical mechanism in Figure 3. Interestingly
we found a different expression of MHC class I molecules as
detected by b2-m and HC10 staining in non-malignant epithelium
and carcinoma (Figure 3). In the former, the b2-m staining was
invariably stronger than the HC10 staining, whereas in carcinoma
the HC10 staining was similar to or stronger than the b2-m staining
(Figure 3). This indicates that the differences in staining of light
and heavy chains of MHC class I are not a consequence of differ-
ences in the sensitivities of the respective antibodies, but rather
reflect differential activation, or deregulation of the respective
genes or gene products during oral carcinogenesis.
MHC class I expression in OSCCs
All OSCCs showed decreased expression of b2-m on the surface
of the neoplastic cells, taking as reference the strong intensity of
staining in the non-malignant mucosa adjacent to carcinomas.
These findings are in agreement with those of Prime et al (1987)
who, using a semi-quantitative technique to measure MHC class I
expression in OSCC, reported a significant loss of b2-m on the
surface of OSCC. A significant association was found between
b2-m staining and HC10 staining, with loss of b2-m being associ-
ated with loss of heavy chain as detected by HC10 antibody.
However, this association was not found when the b2-m results
were compared with HCA2 results. Our explanation for this
finding could be that heavy chains recognized by HCA2 antibody
(mainly of the HLA-A type) might be more stable at the cell
surface in the absence of b2-m than the heavy chains recognized
by HC10 (mainly of the HLA-B/C types). The underlying mecha-
nism of b2-m weak expression could involve deletion or mutation
in the b2-m gene, in analogy with other well studied tumours
(Klein et al, 1967; Rosa et al, 1983; D’Urso et al, 1991; Bicknell
et al, 1994). Alternatively, it could result from a post-translational
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Figure 2 (A) Well-differentiated OSCC (Table 1, T43) showing: (A1) strong expression of MHC class I heavy chain as detected by HC10 antibody; (A2)
numerous CD8+ lymphocytes surrounding tumour islands; (A3) less numerous amount of CD57+ cells surrounding tumour nests; (A4) granzyme B +
lymphocytes infiltrating neoplastic areas. (B) Well to moderately-differentiated OSCC (Table 1, T1) showing: (B1) no expression of MHC class I heavy chain in
the cell membrane, as detected by HC10 antibody; (B2) scarce CD8+ cells infiltrating tumour areas; (B3) scarcely isolated CD57+ cells in the tumour area; (B4)
absence of granzyme B + cells within areas of tumour infiltrating lymphocytes. Size bars represent 60 mm (A1–A3, B1–B3) and 15 mm (A4, B4)mechanism such as sequestering of the b2-m protein by a viral or
other protein, in analogy with the mechanism described for
cytomegalovirus down-regulation of MHC class I molecules
(Chapman and Bjorkman, 1998).
In some OSCCs MHC class I heavy chain was detected in the
cell surface, in spite that no b2-m could be detected. We antici-
pated that these OSCCs would not be efficient in activating CTL
responses, due to conformational alterations and/or impaired
stability of the complexes. Therefore, we analysed granzyme B
expression, as a marker of activation of cytotoxic cells. We choose
this activation marker of cytoxicity, because the secretory path-
way of perforin/granzymes is assumed to play a key role in the
cytotoxic immune response against tumour cells.
Cytotoxic activation of CTLs and NK cells in OSCCs
Since CTL responses are MHC class I restricted, we already
expected poor CTL activation, after demonstration of MHC class I
down-regulation in OSCCs. Interestingly, we also found a con-
siderably low proportion of NK cells infiltrating these tumours.
These numbers may even be lower than estimated, since CD57
monoclonal antibody can detect a subset of human T lymphocytes
in addition to NK cells.
Although we found poor activation of CTLs, as detected by
granzyme B expression, a correlation between the number of
activated CTLs and MHC class I expression was not found when
comparing individual cases. As pointed out before, peptide presen-
tation by MHC class I molecules, although being essential, is not
the only factor that plays a role in the activation of CTLs.
Similarly, it is expected that the absence of MHC class I molecules
will not be the exclusive factor to determine NK cell activation.
The presence or absence of co-stimulatory molecules (e.g. B7) in
the antigen-presenting cell, as well as the type of ligands on CTLs
with which it interacts (e.g. CD28 versus CTLA-4), may result in
enhancement or inhibition of the cytotoxic cell to kill its target
(Chambers and Allison, 1997). Moreover, the type of cytokines
produced by CD4+ helper T-cells influence the type of immune
response. In this context, the interaction of interleukin-2 (IL-2)
with its receptor on the cytotoxic cell seems crucial for expansion
of cytotoxic cells (Whiteside et al, 1996; Gomez et al, 1998),
whereas IL-10 inhibits cellular immune responses (Ding et al,
1993). In addition, in a proportion of OSCCs, functional impair-
ment of T lymphocytes infiltrating these tumours was found to be
due to abnormalities in the zeta-chain of these lymphocytes
(Reichert et al, 1998). Another mechanism of immune escape
might occur when tumour cells (abnormally) express Fas-L
acquiring the ability to induce apoptosis in Fas-expressing TILs.
This has been shown to occur in oesophageal carcinoma (Bennet
et al, 1998).
At present we do not know which of these mechanisms might
explain the lack of a direct relationship between MHC class I
expression and activation of cytotoxic cells (CTLs/NK cells).
The study of Bontkes et al (1997) gives some support to our
findings. These authors analysed the proportion of activated CTLs
and NK cells in cervical cancer and its prestages, by means of
granzyme B staining, but they also did not find a correlation
between granzyme B-expressing cells and the MHC class I expres-
sion in the tumours. Interestingly, in that study granzyme B + cells
were always found in every tumour and the mean values of
granzyme B-expressing cells was generally higher than the values
found in this study. Indeed, in the cervical SCCs studied, the
percentage of CD8+ lymphocytes that were positive for granzyme
B varied between 15% and 100%. Since in both studies the anti-
body used to detect granzyme B was the same, these findings
support studies indicating that the cellular immune response in
patients with head and neck cancer is particularly poor (Wanebo
et al, 1975; Lichtenstein et al, 1980).
In conclusion, this study shows that weak or absent expression
of b2-m light chain of MHC class I molecules are extremely
frequent in OSCCs, and likely to be an important mechanism of
immune evasion for OSCC cells. This hypothesis is supported by
the finding of very low numbers of activated CTLs and NK cells as
detected by granzyme B expression. The fact that a clear correla-
tion between the relative proportion of CTLs/NK cells and MHC
class I expression was not always apparent in the individual cases
suggest that local immune suppression conveyed by cytokines
such as IL-10 (Ding et al, 1993), and other inhibitory local factors
or functional abnormalities of TILs, are likely to play a role in
immune evasion of the neoplastic cells in OSCC.
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